Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

Acute Kidney Injury (AKI) Clinical Trial

Official title:

A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03941483
• Other study ID #: 1128-CL-0201
• Status: Completed
• Phase: Phase 2
• Start date: November 1, 2019
• Est. completion date: October 20, 2021

Study information

• Verified date: April 2023
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy of postsurgery treatment with ASP1128 in subjects at risk for AKI following CABG and/or valve surgery. This study also investigated the safety and tolerability of postsurgery treatment with ASP1128, and pharmacokinetic characteristics of ASP1128 in subjects at risk for AKI following CABG and/or valve surgery.

Description:

The study comprised of a screening visit, followed by CABG and/or valve surgery on Day 1, double-blind treatment period and a follow-up period up to Day 90 in subjects with moderate/severe risk of AKI at 2-22 hours post-surgery. Subjects with low risk of AKI at 2-22 hours post-surgery assessment were enrolled in the observational cohort to evaluate subject characteristics and biomarkers for exploratory objectives.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 351
• Est. completion date: October 20, 2021
• Est. primary completion date: July 26, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years and older

Eligibility

Inclusion Criteria:

• Subject agrees not to participate in another interventional study after signing the informed consent form and until the end of study (EoS) visit has been completed.
• Subject is = 35 years of age at the time of screening (visit 1).
• Subject undergoing non-emergent open chest cardiovascular surgery with the use of cardiopulmonary bypass pump (CPB) (i.e., coronary artery bypass graft (CABG) and/or valve surgery [including aortic root and ascending aorta surgery without circulatory arrest]) within 4 weeks of screening (visit 1).
• Subject is at risk of developing acute kidney injury (AKI) following cardiovascular

surgery, i.e., has 1 or more of the following AKI risk factors:

• Age at screening of = 70 years
• Documented history of eGFR < 60 mL/min per 1.73 m^2 as per Modification of Diet in Renal Disease Study (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (or documented measured glomerular filtration rate assessment) (history needs to be present for at least 90 days prior to screening, and eGFR at screening or baseline needs to be < 60 mL/min per 1.73 m^2, as well as per CKD-EPI equation.)
• Documented history of congestive heart failure requiring hospitalization. This condition should exist for = 90 days prior to screening.
• Documented history of diabetes mellitus (type 1 or 2) of = 90 days prior to screening, and subject is on active antidiabetic medication treatment for = 90 days.
• Documented history of proteinuria/albuminuria at any time point before screening (urinary dipstick result of = 2+, documented urinary albumin creatinine ratio measurement of = 300 mg/g, or documented total quantity of protein in a 24-hour urine collection test = 0.3 g/day)
• Subject must have the ability and willingness to return for all scheduled visits and perform all assessments.
• Female subject is eligible to participate if she is not pregnant and at least 1 of the

following conditions applies:

• Not a woman of childbearing potential (WOCBP), OR
• WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 30 days after the final study drug administration.
• Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 30 days after the final study drug administration.
• Female subject must not donate ova starting at screening and throughout the study period, and for 30 days after the final study drug administration.
• Male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period and for at least 30 days after the final study drug administration.
• Male subject must not donate sperm during the treatment period and for at least 30 days after the final study drug administration.
• Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 30 days after the final study drug administration. Exclusion Criteria:

At Screening:

• Subject has received investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening.
• Subject has received RRT within 30 days prior to screening.
• Subject has CKD stage 4 or 5, or stage 3 (i.e., eGFR 30-59 mL/min per 1.73m^2) with a known history of eGFR < 30 mL/min per 1.73 m^2 as per CKD-EPI or MDRD equation within 6 months prior to screening.
• Subject has a prior kidney transplantation.
• Subject has a known or suspected glomerulonephritis (other than Diabetic Kidney Disease).
• Subject has confirmed or treated endocarditis or other current active infection requiring antibiotic treatment within 30 days prior to screening.
• Subject is using prohibited.
• Subject has a prior history of intravenous drug abuse within 1 year prior to screening.
• Subject has a known chronic liver disorder with Child-Pugh B or C classification.
• Subject has any of the following abnormal liver or kidney function parameters:
• Alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2 times the upper limit of normal (ULN) or bilirubin increased to > 1.5 times the ULN.
• eGFR < 30 mL/min per 1.73 m^2 as per CKD-EPI equation.
• Subject has use of left ventricular assist device, intra-aortic balloon pump or other cardiac devices, or catecholamines within 7 days prior to screening.
• Subject has surgery scheduled to be performed without CPB (i.e., "Off-Pump" surgery).
• Subject has surgery scheduled to be performed under conditions of circulatory arrest, including planned deep hypothermic circulatory arrest.
• Subject has surgery scheduled for aortic dissection.
• Subject has surgery for a condition that is immediately life-threatening.
• Subject has surgery scheduled to correct major congenital heart defect.
• Subject has current or previous malignant disease. Subjects with a history of cancer are considered eligible if the subject has undergone therapy and the subject has been considered disease free or progression free for at least 5 years. Subject with completely excised basal cell carcinoma or squamous cell carcinoma of the skin and completely excised cervical cancer in situ are also considered eligible.

Preoperatively on the Day of Surgery:

• Exclusion criteria 1 to 17 are applicable at this time.
• Subject has AKI (any stage) present at presurgery baseline.
• Subject has known or suspected infection/sepsis at time of presurgery baseline.

Perioperative Exclusion Criteria:

• Subject requires Extracorporeal Membrane Oxygenation during or after completion of surgery.
• Subject requires ventricular assist device during or after completion of surgery.
• Subject has surgery performed "Off-Pump" at any time during surgery.

General:

• Subject has other condition, which makes the subject unsuitable for study participation.
• Female subject who is pregnant or lactating or has a positive pregnancy test within 72 hours prior to screening and/or randomization, has been pregnant within 6 months before screening assessment or breastfeeding within 3 months before screening or who is planning to become pregnant within the total study period.
• Subject has a known or suspected hypersensitivity to ASP1128 or any components of the formulation used.

Related Conditions & MeSH terms

• Acute Kidney Injury
• Acute Kidney Injury (AKI)
• Wounds and Injuries

Intervention

Drug:
• ASP1128
Intravenous Infusion
• Placebo
Intravenous Infusion

Locations

Country	Name	City	State
United States	Morton Plant Hospital	Clearwater	Florida
United States	Fairview Hospital - Cleveland Clinic	Cleveland	Ohio
United States	MercyOne Iowa Heart Center	Des Moines	Iowa
United States	Duke University Medical Center	Durham	North Carolina
United States	Health Park Medical Center	Fort Myers	Florida
United States	Luthern Medical Group	Fort Wayne	Indiana
United States	Shands Hospital	Gainesville	Florida
United States	Ascension Genesys Hospital	Grand Blanc	Michigan
United States	Moses H. Cone Memorial Hospital	Greensboro	North Carolina
United States	Heart Center Research, LLC	Huntsville	Alabama
United States	IU Health - Methodist	Indianapolis	Indiana
United States	St. Vincent Heart Center	Indianapolis	Indiana
United States	Baptist Medical Center	Jackson	Mississippi
United States	St. Luke's Hospital of Kansas City	Kansas City	Missouri
United States	Mid Michigan Medical Center	Midland	Michigan
United States	Minneapolis Heart Institute	Minneapolis	Minnesota
United States	WVU Heart and Vascular Institute	Morgantown	West Virginia
United States	Indiana University Health Ball Memorial Hospital	Muncie	Indiana
United States	Vanderbilt University	Nashville	Tennessee
United States	Baylor Scott & White Heart Hospital	Plano	Texas
United States	Delmarva Heart, LLC	Salisbury	Maryland
United States	University of Texas Health Science Center	San Antonio	Texas
United States	Southern Illinois University	Springfield	Illinois
United States	Florida Hospital Pepin Heart Institute	Tampa	Florida
United States	ProMedica Toledo Hospital	Toledo	Ohio
United States	Sarver Heart Center	Tucson	Arizona
United States	Lourdes Cardiology Services	Voorhees	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Developing AKI Based on Serum Creatinine (SCr) Criteria Within 72 Hrs From End of Surgery (AKI-SCr72h)	Development of AKI was based on SCr criteria from the kidney disease improving global outcomes (KDIGO) guideline (i.e., increase in SCr = 0.3 milligram per deciliter (mg/dL) [= 26.5 micromoles per liter {µmol/L}] within any 48 hours or increase in SCr to = 1.5 times baseline within 72 hours after end of surgery [T0]). Percentage of participants who developed AKI-SCr72h were reported.	From end of surgery up to 72 hrs
Secondary	Percentage of Participants Developing AKI Based on Serum Creatinine (SCr) Criteria Within 7 Days From End of Surgery (AKI-SCr7d)	Development of AKI was based on SCr criteria from the KDIGO guideline (i.e., increase in SCr = 0.3 mg/dL [= 26.5 µmol/L] within any 48 hours or increase in SCr to = 1.5 times baseline within 7 days after T0). Percentage of participants who developed AKI-SCr7d were reported.	From end of surgery up to 7 days
Secondary	Percentage of Participants Developing AKI Based on All Captured Criteria Within 72 Hrs From End of Surgery (AKI-KDIGO72h)	Development of AKI was based on all captured criteria from KDIGO guideline (i.e., AKI-SCr stage 1 to 3: increase in SCr = 0.3 mg/dL [= 26.5 µmol/L] within any 48 hours, increase in SCr to = 1.5 times baseline, and/or AKI-urinary output (UO) stage 2 and 3: urine volume < 0.5 mL/kg per hour for 12 consecutive hours) within 72 hours after T0. Percentage of participants who developed AKI-KDIGO72h were reported.	From end of surgery up to 72 hrs
Secondary	Percentage of Participants Developing AKI Based on All Captured Criteria Within 7 Days From End of Surgery (AKI-KDIGO7d)	Development of AKI was based on all captured criteria from KDIGO guideline (i.e., AKI-SCr stage 1 to 3: increase in SCr = 0.3 mg/dL [= 26.5 µmol/L] within any 48 hours, increase in SCr to = 1.5 times baseline, and/or AKI-urinary output (UO) stage 2 and 3: urine volume < 0.5 milliliter per kilogram (mL/kg) per hour for 12 consecutive hours) within 7 days after T0. Percentage of participants who developed AKI-KDIGO7d were reported.	From end of surgery up to 7 days
Secondary	Percentage of Participants With Major Adverse Kidney Events (MAKE) Within 30 Days After Day of Surgery (MAKE30)	MAKE30 was defined as all-cause mortality, renal replacement therapy (RRT) and/or = 25% sustained reduction in estimated glomerular filtration rate (eGFR) based on SCr within 30 days after day of surgery. Percentage of participants with MAKE30 were reported.	From day of surgery up to 30 days
Secondary	Percentage of Participants With MAKE Within 90 Days After Day of Surgery (MAKE90)	MAKE90 was defined as all-cause mortality, renal replacement therapy (RRT) and/or = 25% sustained reduction in estimated glomerular filtration rate (eGFR) based on SCr within 90 days after day of surgery. Percentage of participants with MAKE90 were reported.	From day of surgery up to 90 days

External Links

•   Link to plain language summary of the study on the Trial Results Summaries website
•   Link to results and other applicable study documents on the Astellas Clinical Trials website